Literature DB >> 3079479

Current status of antitumor therapy with monoclonal antibodies.

D A Scheinberg1, A N Houghton.   

Abstract

The potential power of monoclonal antibodies arises from their ability to recognize single antigenic determinants in a complex mixture of molecules or cells. The possibilities for cancer therapy are apparent. But to what extent has the potential been realized? What problems have arisen in clinical trials?

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3079479

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


  3 in total

1.  Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells.

Authors:  F J Primus; T K Pendurthi; P Hutzell; S Kashmiri; D C Slavin; R Callahan; J Schlom
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

Authors:  A F LoBuglio; R H Wheeler; J Trang; A Haynes; K Rogers; E B Harvey; L Sun; J Ghrayeb; M B Khazaeli
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

3.  Expression behavior of 85-kDa membrane protein in adriamycin-resistant tumor cells and the inhibition of human tumor growth in athymic mice by MRK-20 monoclonal antibody against the protein.

Authors:  S Ishii; M Naito; T Tsuruo
Journal:  Jpn J Cancer Res       Date:  1993-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.